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Abstract
Background: Endogenous defense against oxidative stress is controlled by nuclear factor erythroid 2-related factor
2 (Nrf2). The normal compensatory mechanisms to combat oxidative stress appear to be insufficient to protect
against the prolonged exposure to reactive oxygen species during disease. Counterbalancing the effects of
oxidative stress by up-regulation of Nrf2 signaling has been shown to be effective in various disease models where
oxidative stress is implicated, including Alzheimer’s disease. Stimulation of Nrf2 signaling by small-molecule
activators is an appealing strategy to up-regulate the endogenous defense mechanisms of cells.
Methods: Here, we investigate Nrf2 induction by the metal chelator and known nuclear factor-κB inhibitor
pyrrolidine dithiocarbamate (PDTC) in cultured astrocytes and neurons, and mouse brain. Nrf2 induction is further
examined in cultures co-treated with PDTC and kinase inhibitors or amyloid-beta, and in Nrf2-deficient cultures.
Results: We show that PDTC is a potent inducer of Nrf2 signaling specifically in astrocytes and demonstrate the critical
role of Nrf2 in PDTC-mediated protection against oxidative stress. This induction appears to be regulated by both
Keap1 and glycogen synthase kinase 3β. Furthermore, the presence of amyloid-beta magnifies PDTC-mediated
induction of endogenous protective mechanisms, therefore suggesting that PDTC may be an effective Nrf2 inducer in
the context of Alzheimer’s disease. Finally, we show that PDTC increases brain copper content and glial expression of
heme oxygenase-1, and decreases lipid peroxidation in vivo, promoting a more antioxidative environment.
Conclusions: PDTC activates Nrf2 and its antioxidative targets in astrocytes but not neurons. These effects may
contribute to the neuroprotection observed for PDTC in models of Alzheimer’s disease.
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Background
Oxidative stress results from an imbalance in the pro-
duction and removal of reactive oxygen species (ROS)
[1–3] and leads to induction of defensive gene expres-
sion that aims to detoxify ROS and promote cell survival
[4]. An important transcription factor in the defense
against oxidative stress is nuclear factor erythroid 2-
related factor 2 (Nrf2). Nrf2 binds to the antioxidant
response element (ARE) and induces the expression of
ARE-driven cytoprotective genes, including heme
oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase-
1 (NQO1), and glutamate-cysteine ligase (GCL), the rate-
limiting enzyme of glutathione synthesis consisting of cata-
lytic (glutamate-cysteine ligase catalytic subunit (GCLC))
and modifier (glutamate-cysteine ligase modifier subunit
(GCLM)) subunits [5–7]. Nuclear Nrf2 abundance is regu-
lated by positive and negative stimuli that affect nuclear
import and export, binding to the ARE, and degradation
[8, 9]. In the central nervous system, it appears that astro-
cytes, the most abundant glial cell type that possess im-
portant functions in the maintenance of brain homeostasis,
have been implicated as the main target of Nrf2 activation
[10] and increase their release of glutathione in response to
Nrf2 activation [11].
During aging and disease, the normal compensatory
mechanisms to combat ROS-mediated damage appear to
be insufficient. Consistent with this, the level of nuclear
Nrf2 is reduced in the hippocampus of Alzheimer’s
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disease (AD) brain [12], and attenuation of the Nrf2-
ARE pathway coincides with disease progression in
transgenic AD mice [13, 14], while genetic ablation of
Nrf2 increases AD-associated pathology in AD mice
[15]. Conversely, we have earlier shown that long-term
overexpression of Nrf2 specifically in hippocampal neu-
rons ameliorates memory deficits in a mouse model of
AD [16] and transduction of primary neurons with Nrf2
protects against amyloid-beta (Aβ) toxicity [13].
In addition to overexpression, stimulation of the Nrf2-
ARE pathway by small-molecule activators appears an ap-
pealing strategy to up-regulate the endogenous defense
mechanisms of cells. At least nine classes of Nrf2-inducing
agents have been described [17] with sulforaphane and tert-
butylhydroquinone the most widely studied in the central
nervous system [9, 18–20]. Some small-molecule activators
have been used to assess their potential protective action in
mouse models of AD [21–23], while dimethyl fumarate
(Tecfidera®) has recently been approved for clinical use for
relapsing form of multiple sclerosis [24].
Pyrrolidine dithiocarbamate (PDTC) is a blood-brain
barrier permeant metal-chelating compound possessing
antioxidant and anti-inflammatory properties. Many
studies have reported induction of endogenous antioxi-
dant gene expression and cytoprotective proteins by
PDTC [25–29] and inhibition of nuclear factor-κB (NF-
κB) [30–33]. The protective function of PDTC in animal
models of central nervous system disorders has also
been explored in several studies [34–40], while we and
others have shown that PDTC is protective in AD mouse
models [41, 42]. The protective mechanism of action of
PDTC in AD involves modulation of brain copper con-
centration, glycogen synthase kinase 3β (GSK3β), and
glial glutamate transporters, as well as suppression of
NF-κB signaling. While we have recently shown that
PDTC increases the proliferation of neural stem/pro-
genitor cells in a manner similar to that caused by Nrf2
overexpression [43], the involvement of Nrf2 in PDTC-
mediated effects remains unknown.
The present study aimed to explore the effect of PDTC
on Nrf2 induction in normal conditions and in a setting of
elevated Aβ. Here, we report that (i) Nrf2 is required for
the PDTC-mediated enhancement of cellular resistance to
oxidative damage, (ii) PDTC-induced Nrf2 activation oc-
curs preferentially in astrocytes, and (iii) PDTC-mediated
Nrf2 induction is amplified in the presence of Aβ.
Methods
Primary adult astrocyte culture
Cortices were isolated from 6- to 8-week-old C57Bl/6J
mice and the Nrf2-disrupted C57BL/6JJcl mice generated
by Itoh et al. [44] as described previously [45]. Following
dissociation, the tissue was suspended in DMEM/F12 (3:1,
Gibco) containing 10 % FBS and 100 U/mL penicillin-
streptomycin (Gibco). The suspension was triturated and
centrifuged at 1500 rpm for 5 min at room temperature.
After adding 0.25 % trypsin-EDTA (Gibco), the suspension
was incubated at 37 °C for 30 min. Fresh culture medium
was added, and the suspension was centrifuged at 1500 rpm
for 5 min. The cells were treated with 27 % Percoll (Sigma-
Aldrich) in culture media, centrifuged at 1500 rpm for
10 min and washed once with fresh culture media. The cells
were plated onto poly-L-lysine coated flasks in DMEM/F12
(3:1) containing 10 % FBS, 100 U/mL penicillin-
streptomycin, and G5 supplement (Gibco). Cells were used
between passages 3 and 7. These cultures are 99.8 % GFAP-
positive, as determined by immunocytochemistry [45].
Primary neonatal astrocyte culture
Primary astrocyte cultures were prepared from neonatal
mice according to the method of Hamprecht and Löffler
[46]. Briefly, as previously described [47], brains removed
from newborn C57BL/6J mouse pups were mechanically
dissociated by sequential passes through 250 and 135 μm
nylon mesh, centrifuged at 500×g for 5 min before resus-
pension in DMEM supplemented with 50 U/mL penicillin-
streptomycin and 10 % FBS and plated at 160,000 cells/
cm2. The medium was renewed every 7 days, and cultures
were used between 15 and 21 days in vitro, 1–2 days after
medium renewal. Immunocytochemical analysis shows
these cultures contain approximately 80 % GFAP-positive
astrocytes with the remainder mainly IBA1-positive micro-
glia but no neurons (data not shown).
Primary hippocampal neuron culture
Hippocampi were dissected from embryonic day 18
mouse fetal brains and prepared as described previously
[13]. Following dissociation, the cells were suspended in
Neurobasal culture medium supplemented with 2 % B27,
500 μM glutamine, 25 μM glutamate, and 1 % penicillin-
streptomycin (Gibco) and plated on 24- or 48-well culture
plates precoated with poly-ornithine (0.5 μg/μL, Sigma-
Aldrich) at 400,000 or 200,000 cells/well, respectively.
One day after plating, the medium was supplemented with
10 μM cytosine β-D-arabinofuranoside and cells were
grown in this media for 3 days prior to changing to media
devoid of cytosine β-D-arabinofuranoside. Five days after
plating, one third of the media was changed. Cells were
treated at 7 days after harvesting. About 90 % of cells in
these cultures are neurons [13].
Primary mixed cortical culture
Primary mixed cultures of cortical neurons and astrocytes
were prepared from embryonic day 14 mouse brains and
maintained in neurobasal medium supplemented with
500 μM glutamine, 10 μg/mL gentamycin, and 2 % B27 as
previously described [47]. Cells were used at 8 days in vitro,
2 days after renewal of medium. Neurons account for
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approximately 60–70 % of cells in these cultures, as deter-
mined by immunocytochemical staining for MAP-2 (data
not shown).
Cell treatments
PDTC (Sigma-Aldrich) was dissolved in sterile water
and used immediately after preparation. The kinase
inhibitors 10-DEBC, FPA-124, LY294002, PD198306,
PD98059, PI828, SB415286, and SL327 (Tocris) were
dissolved in DMSO to 10 mM. Aβ(1-42) was purchased
from American Peptide (Sunnyvale, CA) and dissolved
to 1 mg/mL in sterile water. Protein concentration of
the peptide was verified by DC protein assay kit (Bio
Rad). The soluble peptide was used for experiments im-
mediately after preparation as described [13].
Viability assays
Cell viability following treatments was assessed by kinet-
ically measuring the release of lactate dehydrogenase
(LDH) into the culture medium using an LDH determin-
ation kit (Sigma-Aldrich/Roche). MTT reduction was
assessed following incubation of cells with 480 μM MTT
for 1 h before lysing in DMSO and quantifying absorb-
ance at 560 nm. The data are expressed as percentage of
control. For counting purposes, cells were fixed in 4 %
paraformaldehyde for 30 min, stained with Hoechst, and
enumerated from at least nine fields/treatment.
Immunocytochemistry
After treatment, cells were fixed with 4 % paraformalde-
hyde for 20 min before blocking and permeabilizing in
PBS containing 1 % BSA and 0.3 % triton X-100. Cells
were subsequently incubated with antibody to Nrf2
(1:1000, Cell Signaling Technology (CST) #12721), MAP2
(1:1000; Chemicon, Merck Millipore), or GFAP (1:1000;
Dako) overnight at 4 °C before further incubation with
AlexaFluor-488, AlexaFluor-568, or AlexaFluor-647 second-
ary antibodies (1:250) for 1 h at room temperature. Before
mounting onto microscope slides, cells were incubated with
0.5 μg/mL DAPI for 5 min. Cells were imaged with a Zeiss
LSM Meta confocal microscope. Nuclear fluorescence in-
tensity of Nrf2 was determined from approximately
500–700 cells per condition using ImageJ software.
Nuclear fractionation
Following treatment, cells were washed twice with ice-
cold PBS, collected into the PBS and centrifuged at
720×g for 3 min. Pellets were lysed in lysis buffer
(50 mM Tris/HCl, 0.5 % triton X-100, 137.5 mM NaCl,
10 % glycerol, 1 mM sodium vanadate, 50 mM sodium
fluoride, 10 mM sodium pyrophosphate, 5 mM EDTA,
1 % protease inhibitor cocktail (Sigma-Aldrich), pH 7.5)
and resultant homogenates centrifuged at 15,000×g for
15 min. The supernatant was collected as cytosolic
fraction before the pellet was rinsed with lysis buffer,
re-centrifuged, and resuspended in lysis buffer contain-
ing 0.5 % SDS. Homogenates were sonicated before cen-
trifuging at 15,000×g for 15 min and the supernatant
collected as nuclear fraction. Samples were maintained
at 4 °C throughout the procedure. Protein content was
determined by BCA assay (Pierce).
Gel electrophoresis and western blots
Proteins were harvested with PhosphoSafe buffer (Merck)
containing protease inhibitor complete tablet (Complete,
Roche Applied Sciences, Mannheim, Germany) or lysis
buffer (as above). Proteins were separated on 12 % SDS-
PAGE Tris-glycine gels. Proteins were transferred to
PVDF membrane using Mini Trans-blot electrophoretic
transfer cell equipment (Bio Rad) or Novex mini gels
(Invitrogen) and then blocked in a solution of 5 % non-fat
dry milk in 0.2 % Tween-20/0.01 M PBS for 30 min. For
immunodetection of separated proteins, the membranes
were incubated overnight at +4 °C with the following
primary antibodies: HO-1 (Stressgen or CST), NQO1
(Abcam), Nrf2 (Santa Cruz Biotechnology or CST), Keap1
(CST), phospho-Akt (Ser473; CST), phospho-ERK1/2
(Thr202/Tyr204; CST), phospho-GSK3α/β (Ser21/9; CST),
and β-actin (CST), GAPDH (CST), or histone H3 (CST)
for loading controls. For detection, the membranes were in-
cubated with HRP-conjugated Ig anti-rabbit, anti-mouse, or
anti-goat secondary antibodies (1:5000; CST) for 2 h, devel-
oped using enhanced chemiluminescence (GE Healthcare
ECL Advance Chemiluminescence kit) and imaged on a
Fujifilm LAS3000 Imager (Berthold).
Quantitative real-time PCR
RNA was isolated with RiboPure RNA kit (Life Tech-
nologies), and 500 ng of total RNA was used for cDNA
synthesis using random hexamer primers (Promega,
Madison, WI) and M-MuLV reverse transcriptase (New
England Biolabs, Ipswich, MA) or Maxima reverse tran-
scriptase (Thermo Scientific). The relative expression
levels of mRNA encoding HO-1, GCLM, GCLC, NQO1,
and Nrf2 were measured according to manufacturer’s
protocol by quantitative RT-PCR (ABI PRISM 7700 Se-
quence detector, Applied Biosystems, Foster City, CA)
using specific Assays-On-Demand target mixes (Applied
Biosystems/Invitrogen). The expression levels were nor-
malized to β-macroglobulin or β-actin and are presented
as fold change in the expression over control.
Glutamate-cysteine ligase activity assay
GCL activity was determined according to a modified
method of White et al. [48]. Following treatment, cells
were washed twice with ice-cold PBS before hypotonic
lysis in 20 mM KPi for 10 min on ice. Cells were
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quantitatively collected and centrifuged at 15,000×g for
10 min before 50 μL samples of supernatant were com-
bined with 50 μL 400 mM Tris pH 7.4, 20 mML-glu-
tamic acid, 2 mM EDTA, 20 mM sodium borate, 2 mM
L-serine, 40 mM MgCl2, and 40 mM ATP. For detection
of basal glutathione and γ-glutamylcysteine content, dupli-
cate 50 μL samples were combined with the same plus
addition of 2 mML-buthionine sulfoximine to inhibit GCL
activity. Samples were warmed to 37 °C, and the GCL reac-
tion was initiated by addition of 2 mML-cysteine in
20 mM Tris pH 7.4, 1 mM EDTA, 250 mM sucrose,
20 mM sodium borate, and 2 mML-serine. After incuba-
tion for 1 h at 37 °C, the GCL reaction was halted by
addition of 50 μL ice-cold 200 mM sulfosalicylic acid. Ali-
quots (20 μL) were combined with reaction mix to final
concentration of 1 mM 2,3-naphthalenedicarboxyaldehyde
in 50 mM NaOH and 35 mM Tris for 30 min before fluor-
escence intensity was determined at 470ex/530em on an
EnSpire multimode reader (PerkinElmer). Glutathione was
used as standards. The difference between values in the ab-
sence and presence of L-buthionine sulfoximine is propor-
tional to GCL activity, given as nmol γ-glutamylcysteine
(γGC) generated per minute per milligram protein.
Glutathione assay
Total glutathione content was determined according to the
method of Tietze [49] as described previously [50]. For de-
termination of cellular glutathione, 10 μL samples of cell ly-
sates in 1 % sulfosalicylic acid were analyzed. For media
analysis, one part medium was combined with one part
water and two parts 1 % sulfosalicylic acid, and 20 μL of
this was analyzed. Following addition of reaction mix to a
final concentration of 200 μM NAPDH, 150 μM 5,5′-
dithiobis-(2-nitrobenzoic acid), and 0.1 U glutathione
reductase (Sigma-Aldrich) in 50 mM NaPi buffer pH 7.5
containing 0.5 mM EDTA, the rate of thionitrobenzoate
production was followed spectrophotometrically at 405 nm.
Animal experiments
Starting from the age of 6 months, C57BL/6J wild-type
(WT) mice were treated with PDTC (20 mg/kg/day) in
drinking water for 9 months as previously described [41]
(n = 6–8/group). A second cohort of mice was treated for
2 weeks at a dose of 75 mg/kg/day. The mice were deeply
anesthetized with avertin and transcardially perfused with
heparinized saline after which the brain was dissected and
snap-frozen in liquid nitrogen. Brain tissue was also col-
lected from Nrf2-deficient C57BL/6JJcl mice generated by
Itoh et al. [44]. All animal work was approved by the
National Animal Experiment Board of Finland (license
number ESAVI-2011-000855) and followed the guidelines
of the Council of Europe Legislation and Regulation for
Animal Protection.
Immunohistochemistry
Pentobarbital-anesthetized mice were transcardially
perfused with heparinized saline. The brains were
immersion-fixed with 4 % paraformaldehyde for 21 h and
cryoprotected in 30 % sucrose for 48 h. The brains were
frozen on liquid nitrogen and cut to 20-μm-thick cryosec-
tions. Sections were immunostained with HO-1 (Stressgen
or CST) and GFAP (DakoCytomation, Glostrup, Denmark)
overnight at room temperature. Primary antibody binding
was detected by using Alexa Fluor 568-conjugated second-
ary antibody for HO-1 and Alexa Fluor 488-conjugated
secondary antibody for GFAP (Invitrogen, Eugene, OR).
The hippocampal dentate gyrus area from four to six
sections in 200-μm intervals through the hippocampi
were evaluated per animal. For quantification, the
sections were imaged with an Olympus AX70 micro-
scope (Olympus, Melville, NY) with an attached
digital camera (Color View 12 or F-View; Soft Im-
aging System, Munster, Germany).
Ferrous oxidation-xylenol orange (FOX) assay
Hippocampal tissues were sonicated in 90 % cold acet-
one solution and centrifuged at room temperature at
10,000×g for 10 min. Hydroperoxides were quantified from
the supernatant based on detection of hydroperoxide-
mediated oxidation of ferrous to ferric ion in the presence
of xylenol orange [51] using hydrogen peroxide standards.
Determination of brain copper content
The copper content of cerebella isolated from mice
treated with PDTC for 2 weeks were measured by ICP-
MS after freeze-drying and acid-digestion in nitric acid
and hydrogen peroxide. The copper concentrations were
determined with ICP-MS using external calibration and
internal standard correction.
Statistical analyses
The data were analyzed by using t test or ANOVA
followed by Dunnett post hoc tests comparing to control
condition in GraphPad Prism software, and statistical
significance was assumed if p < 0.05. Unless otherwise
mentioned, data are expressed as means ± SD.
Results
PDTC induces nuclear translocation of Nrf2 in astrocytes
Primary neurons and astrocytes were harvested from
mouse brain to assess the ability of PDTC to induce the
Nrf2 pathway. When used at 1- to 100-μM concentra-
tions, PDTC did not cause astrocytic cell death as mea-
sured by the LDH release or MTT assay after 24 h
treatment (Additional file 1: Figure S1A–B). PDTC did
not cause death of hippocampal neurons when used at
1- to 50-μM concentrations (Additional file 1: Figure S1C).
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Nrf2 translocation into nuclei was first assessed by im-
munocytochemical staining of primary neonatal astro-
cytes treated with PDTC for 4 h (Fig. 1a). PDTC
treatment induced a significant, tenfold increase in nu-
clear Nrf2 expression in astrocytes (Fig. 1b). A slight,
1.5-fold increase in nuclear Nrf2 was observed in hippo-
campal neurons treated with PDTC (Fig. 1c). Strong nu-
clear Nrf2 induction in mixed cortical cultures was
restricted to MAP2-negative GFAP-positive cells (Fig. 1d).
The specificity of the Nrf2 antibody and lack of PDTC ef-
fect in Nrf2-deficient cells was confirmed by absence of
immunostaining in Nrf2−/− astrocytes (Additional file 2:
Figure S2). Nrf2 translocation was further confirmed by
western blot of neonatal astrocytes after nuclear fraction-
ation (Fig. 1e). PDTC induced a dose-dependent increase
in the levels of nuclear Nrf2 in astrocytes (Fig. 1f).
PDTC induces Nrf2 target genes in astrocytes but not
neurons
Given that PDTC was a strong inducer of Nrf2 nuclear
translocation, we next assessed the potential of PDTC to in-
duce the expression of Nrf2 target genes. A 24-h treatment
with PDTC induced a dose-dependent increase in Nrf2 tar-
get genes in adult astrocytes. HO-1 (Fig. 2a) and GCLM
(Fig. 2b) mRNA expression levels were significantly ele-
vated in astrocytes treated with 1 and 10 μM PDTC but
Fig. 1 PDTC-induced translocation of astrocytic Nrf2. a Representative Nrf2 immunostaining images of primary neonatal astrocytes treated with 10 or
100 μM PDTC for 4 h. Right panels are merged images of Nrf2 (left panels) and the nuclear marker DAPI (center panels). b Quantification of nuclear Nrf2
immunostaining in astrocytes expressed as fold change over control ± SD. c Quantification of nuclear Nrf2 immunoreactivity in hippocampal neurons
treated with PDTC for 4 h. Data are expressed as fold change over control cells ± SD. d Representative immunostaining of mixed cortical cultures
treated with PDTC for 4 h, co-stained for DAPI, Nrf2, the neuronal marker MAP2 and astrocyte marker GFAP. Arrowheads indicate MAP2-negative GFAP-
positive cells with strongly increased nuclear Nrf2. e A representative immunoblot with antibodies against Nrf2, GAPDH (cytosolic marker), and histone
H3 (nuclear marker) with neonatal astrocyte samples treated with PDTC for 4 h. f Quantification of nuclear Nrf2 protein levels after 4 h PDTC treatment
of astrocytes. Data are expressed as fold change over control cells normalized to histone H3 ± SD *p < 0.05; **p < 0.001. Scale bar = 20 μm
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not in hippocampal neurons. PDTC did not increase the
mRNA expression levels of Nrf2, NQO1, or GCLC in either
cell type (data not shown). Protein expression of HO-1 and
the negative regulator of Nrf2, Keap1, was assessed by west-
ern blot in neonatal astrocytes treated with PDTC for 4 h
(Fig. 2c). Keap1 expression decreased while HO-1 was
strongly elevated (Fig. 2d, e).
PDTC treatment increases GCL activity and glutathione
levels in astrocytes
Because Nrf2 induction is known to increase glutathione
biosynthesis in astrocytes, we investigated the potential
of PDTC in this process. A 24-h PDTC treatment
significantly increased GCL activity in neonatal astro-
cytes (Fig. 2f ). Furthermore, cellular glutathione (GSH)
levels and the release of GSH into the media were
increased by PDTC (Fig. 2g, h), indicating that PDTC
has potent antioxidant actions through GSH up-
regulation.
Nrf2 is more readily induced in adult astrocytes as
compared to neonatal astrocytes
Significant up-regulation of HO-1 and GCLM occur with
as little as 1 μM PDTC in adult astrocytes (Fig. 2a, b),
whereas 100 μM PDTC is required to significantly
increase HO-1 expression, GCL activity, and glutathione
Fig. 2 Effect of PDTC treatment on Nrf2 target genes, GCL activity, and glutathione content. a HO-1 and b GCLM mRNA expression levels
measured by quantitative RT-PCR from primary adult astrocyte cultures and hippocampal neuron cultures after 24 h PDTC treatment. The mRNA
expression levels are presented as mean relative expression normalized to β-actin ± SD. c Representative immunoblots with antibodies against
Keap1, HO-1, and GAPDH from neonatal astrocytes treated with PDTC for 4 h. d Quantification of Keap1 and e HO-1 protein levels. Data are
expressed as fold change over control cells normalized to GAPDH ± SD. f Neonatal astrocytes were treated with PDTC for 24 h, before GCL activity
was determined. Data are expressed as mean nanomole γGC produced per minute per milligram protein ± SD. g The cellular glutathione content
was measured after 24 h PDTC treatment of neonatal astrocytes and normalized to cellular protein content ± SD. Data are expressed as nanomole
glutathione content per milligram protein. h Glutathione released into the media from neonatal astrocytes was measured 24 h after PDTC treatment.
Data are shown as nanomole of glutathione released into the well ± SD. *p < 0.05; **p < 0.001 relative to corresponding control
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content in neonatal astrocytes (Fig. 2c, e–g). This in-
dicates that astrocytes cultured from adult mice are
more sensitive to PDTC than astrocytes cultured from
neonatal mice.
Nrf2 induction by PDTC involves kinase phosphorylation
Increased phosphorylation of Akt and ERK1/2 and in-
hibitory phosphorylation of GSK3α/β were increased in
PDTC-treated neonatal astrocytes (Fig. 3a–d), consistent
with Nrf2 activation. The small-molecule GSK3 inhibitor
SB415286 did not alter the PDTC-induced increase
in Nrf2, HO-1, or GSH export but did significantly
increase cellular Nrf2 levels and increase exported
glutathione ~1.7-fold over cells treated in the ab-
sence of PDTC (Fig. 3e–h), suggesting the inhibitory
phosphorylation of GSK3 induced by PDTC contrib-
utes to the activation of Nrf2. Cellular GSH levels
were unchanged (data not shown). Inhibition of the
ERK-activating mitogen-activated protein kinase kinase
(MEK) by SL327, PD198306 or PD98059 did not signifi-
cantly alter Nrf2 or HO-1 protein levels or GSH export
(Additional file 3: Figure S3A–D), nor did inhibition of
PI3K by LY294002 or PI828 and Akt by FPA124 or 10-
DEBC (Additional file 3: Figure S3E–H). These inhibitors
did not significantly decrease cellular GSH (data not
shown) or significantly alter cellular viability with the ex-
ception of FPA124 and PI828, which mildly decreased via-
bility (Additional file 4: Figure S4A-B).
Nrf2 is required for the PDTC-mediated induction of
NQO1 and up-regulation of glutathione biosynthesis
When compared to WT astrocytes, the PDTC-mediated
increases in both cellular and released GSH were signifi-
cantly reduced in Nrf2−/− astrocytes (Fig. 4a, b), indicat-
ing that Nrf2 is central to the GSH-inducing effect of
PDTC. Furthermore, PDTC induced astrocytic protein
expression of HO-1 and NQO1 after 24 h treatment
(Fig. 4c, e, f ). Importantly, NQO1 expression was not in-
duced by PDTC treatment in astrocytes harvested from
Nrf2−/− mice (Fig. 4d, e). Taken together, these results
suggest that Nrf2 is required for PDTC-mediated induc-
tion of both glutathione biosynthesis and induction of
protective protein expression.
Co-treatment of PDTC with amyloid-beta magnifies
Nrf2-ARE induction in astrocytes
We have earlier shown that PDTC treatment [41] and
Nrf2 overexpression [16] are protective in transgenic AD
mice. To investigate the influence of an elevated Aβ-
containing milieu on PDTC-mediated induction of the
Nrf2-ARE, a co-treatment approach was applied. Treat-
ment of hippocampal neurons and adult astrocytes with
5 μM Aβ(1-42) alone caused a small increase in the ex-
pression of Nrf2-controlled HO-1, but not GCLM, after
24 h (Fig. 5a, b).
Co-treating cells for 24 h with Aβ and PDTC resulted in
further substantial increases in astrocytic HO-1 (Fig. 5a),
greater than that observed when treated with PDTC alone.
Fig. 3 Involvement of kinases in Nrf2 induction by PDTC. a Representative immunoblots with antibodies against phosphorylated ERK1/2,
phosphorylated Akt, phosphorylated GSK3α/β, and GAPDH in neonatal astrocytes treated with PDTC for 4 h. b Quantification of pERK1/2,
c pAkt, and d pGSK3α/β protein levels. Data are expressed as fold change over control cells normalized to GAPDH ± SD. e Representative
immunoblots with antibodies against Nrf2, HO-1, and GAPDH in neonatal astrocytes co-treated for 4 h with PDTC and SB415286 (GSK3
inhibitor). f Quantification of Nrf2 and g HO-1 protein expression after 4 h co-treatment of astrocytes with PDTC and SB415286. Data are
expressed as fold change over control cells in absence of inhibitor, normalized to GAPDH ± SD. h Exported glutathione after 4 h PDTC
co-treatment of neonatal astrocytes in presence of SB415286. Data expressed as nanomole glutathione released into the medium per well. *p < 0.05;
**p < 0.01 relative to corresponding control
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Fig. 4 Absence of Nrf2 induction in Nrf2-deficient astrocytes. a Cellular and b released glutathione were determined from WT and Nrf2-deficient
adult astrocytes treated with PDTC for 24 h. Data are expressed as percentage of control cells ± SD. c Representative immunoblots with antibodies
against NQO1, HO-1, and GAPDH from WT astrocyte samples or d NQO1, HO-1, and β-actin from Nrf2−/− astrocyte samples treated with PDTC for
24 h. e Quantification of NQO1 and f HO-1 protein expression in WT (Nrf2+/+) and Nrf2-deficient (Nrf2−/−) astrocytes treated with PDTC for 24 h.
Data are expressed as fold change over control normalized to GAPDH or β-actin ± SD. *p < 0.05; **p < 0.001 relative to corresponding control
Fig. 5 Effect of PDTC and Aβ co-treatment on Nrf2 target genes in primary astrocytes and neurons. a HO-1 and b GCLM mRNA expression levels
were measured by quantitative RT-PCR from primary adult astrocyte cultures and hippocampal neuron cultures after 24 h treatment with 5 μM
Aβ(1-42) with or without co-treatment with 1 μM PDTC. The mRNA expression levels are presented as mean relative expression normalized to
β-actin ± SD. *p < 0.05; **p < 0.001 relative to corresponding control; ap < 0.001 relative to PDTC condition
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Fig. 6 In vivo effects of PDTC on HO-1 expression, copper content and lipid peroxidation. a Representative immunostaining images of brain
sections from WT mice treated with PDTC for 9 months with or without PDTC at a dose of 20 mg/kg/day. HO-1, GFAP, and nuclear DAPI were
imaged from the hippocampal dentate gyrus. b The percentage of glial cells expressing HO-1 in the hippocampal dentate gyrus was calculated
from five WT mice receiving PDTC for 9 months at a dose of 20 mg/kg/day and five vehicle-treated animals. Data are shown as percentage of
HO-1 positive cells ± SD. c Cerebellar copper concentrations were measured from WT mice treated with PDTC for 2 weeks at a dose of 75 mg/kg/day
by ICP-MS and are shown normalized to mass of the tissue ± SD. d Lipid peroxidation in hippocampi of WT mice treated for 9 months with or without
PDTC at a dose of 20 mg/kg/day and in e WT and Nrf2−/− hippocampi were measured by the FOX assay. Data are expressed as μM hydroperoxides
per milligram protein ± SD. *p < 0.05; **p < 0.01
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HO-1 levels in neurons remained unchanged (Fig. 5a).
While astrocytic NQO1 expression was not significantly
increased by Aβ treatment (data not shown), a similar
PDTC-mediated potentiation effect specifically in astro-
cytes was observed for GCLM mRNA expression levels
(Fig. 5b), over that induced by PDTC alone.
Taken together, these results indicate that while the
presence of Aβ slightly induces the expression of Nrf2 tar-
get genes, robust induction of the protective pathway is
only achieved with co-treatment of PDTC and Aβ(1-42),
and this induction appears to be specifically restricted to
astrocytes, not neurons.
PDTC increases glial HO-1 expression and brain copper
content in vivo
To assess the effect of PDTC treatment on expression of
Nrf2 and target genes in the brain, we first measured
mRNA expression levels of NQO1, HO-1, and Nrf2 and
protein expression of Nrf2 and NQO1 in the hippo-
campi of WT mice treated with PDTC for 2 weeks at
75 mg/kg/day and in mice treated for 9 months at a dose
of 20 mg/kg/day. PDTC treatment did not induce Nrf2-
related genes (Additional file 5: Figure S5A–C) or pro-
tein expression of Nrf2 and NQO1 in the hippocampal
tissue homogenates (Additional file 5: Figure S5D–F).
To exclude the possibility that the lack of effect was due
to PDTC not entering the brain, copper levels were
assessed in the brains of PDTC-treated mice. As we have
shown earlier [41], PDTC treatment caused a significant
increase in copper levels in the cerebella (Fig. 6c), indi-
cating that orally administered PDTC penetrated the
brain but failed to induce Nrf2-controled gene and pro-
tein expression when assessed from tissue homogenates.
To assess the in vivo effect of oral PDTC administra-
tion in more depth and to determine the cell-specific
effects of PDTC, we next quantified the protein expres-
sion of HO-1 in the hippocampal dentate gyrus of mice
treated with PDTC for 9 months at a dose of 20 mg/kg/
day. The expression of glial HO-1 was increased in
PDTC-treated animals in the hippocampal dentate gyrus
(Fig. 6a, b). This suggests that in contrast to the lack of
PDTC effect in whole tissue homogenates, significant in-
duction of the Nrf2 target gene HO-1 can be achieved in
specific cell populations.
PDTC treatment enhances resistance to lipid
peroxidation, which is increased in Nrf2 deficiency in vivo
To assess the potential of PDTC in reducing lipid perox-
idation, 6-month-old WT mice were treated orally with
PDTC for 9 months at a dose of 20 mg/kg/day according
to [41]. As assessed by the FOX assay, oral PDTC treat-
ment reduced the amount of hippocampal hydroperox-
ides by 62 % (Fig. 6d), thus providing further evidence
that PDTC enhances cellular resistance to oxidative
damage. Hydroperoxides were increased by 47 % in the
Nrf2−/− hippocampi when compared to WT controls
(Fig. 6e).
Discussion
The crucial function of the Nrf2 pathway in central ner-
vous system disorders is demonstrated by in vivo studies
where Nrf2 induction is associated with improvements
in behavior and functional outcomes, and lack of Nrf2 is
associated with worsened outcome or reduced neuropro-
tection [52–55], including AD [15]. Correspondingly,
Nrf2 appears to be suppressed in the hippocampi of AD
patients [12]. Hence, Nrf2 is emerging as an important
potential therapeutic target. In recent years, a variety of
small-molecule activators of the Nrf2-pathway have been
described. These represent an important pharmaco-
logical means to control Nrf2 activation. The present
study identifies PDTC as a novel inducer of the Nrf2
pathway specifically in astrocytes. This study also finds
that further augmentation of Nrf2 induction by PDTC
occurs in the presence of Aβ and demonstrates the crit-
ical requirement of Nrf2 for the PDTC-mediated en-
hancement of cellular resistance to oxidative damage.
While we have earlier shown that induction of neur-
onal Nrf2 is protective in AD models [13, 16], it is gen-
erally considered that Nrf2 induction occurs primarily in
astrocytes and that this induction confers protection
upon neurons [10, 56–59]. For example, Nrf2-mediated
glutathione release from astrocytes protects neurons
[59]. Indeed, a recent study showed that Nrf2 expression
is specifically repressed in maturing neurons [60]. How-
ever, astrocytic Nrf2 activation can be regulated by neur-
onal activity: increased neuronal synaptic activity and
neurotransmitter release stimulates Nrf2 induction in
co-cultured astrocytes but does not alter Nrf2 signaling
when neurons are cultured alone, suggesting a critical
interplay between neurons and astrocytes in the protect-
ive induction of Nrf2 signaling [61]. The results of the
current study are entirely consistent with these investi-
gations, whereby robust induction of Nrf2 was only evi-
dent in astrocytes, and all but absent in neurons
including when cultured with astrocytes. These results
indicate that astrocytes are more sensitive to PDTC-me-
diated induction of the Nrf2-ARE pathway than neu-
rons. Furthermore, Nrf2 induction was more readily
induced by PDTC in astrocytes cultured from adult
mice as compared to neonatal mice. This is in line
with our previous findings that adult astrocytes ex-
hibit greater alterations in gene expression than neo-
natal astrocytes [62]. The PDTC-conferred
enhancement of protective antioxidative mechanisms
occurs specifically via activation of Nrf2 signaling, as
evidenced by the absence of antioxidant induction in
Nrf2-deficient astrocytes.
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The mechanism via which PDTC induces the Nrf2 re-
sponse likely involves multiple mechanisms, including
decreased degradation, altered biometal homeostasis,
and potential interplay with NF-κB. These will now be
considered. Firstly, PDTC is a well-known inhibitor of
the pro-inflammatory transcription factor NF-κB. How-
ever, there is much evidence for complex crosstalk be-
tween Nrf2 and NF-κB. Nrf2 can directly and indirectly
suppress NF-κB signaling, whereas NF-κB can both
amplify and diminish Nrf2 signaling [63, 64]. NF-κB can
decrease Nrf2 binding to DNA by competing for co-
activators and promoting a co-repressor [65]. Con-
versely, NF-κB can enhance Nrf2 signaling by promoting
Nrf2 transcription [63]. It is unclear whether PDTC pro-
motes Nrf2 signaling via inhibition of NF-κB or whether
the well-known NF-κB inhibitory effects of PDTC are at
least in part due to Nrf2 activation. Clearly, further stud-
ies are required to delineate the relationship between
NF-κB inhibition and Nrf2 induction by PDTC.
The slight increase in cytosolic Nrf2 in addition to in-
creased nuclear Nrf2 suggests that PDTC may stimulate
de novo synthesis of Nrf2. Decreased cytosolic degrad-
ation is also likely to contribute to the observed eleva-
tions in Nrf2. Keap1 is a negative regulator of Nrf2 that
promotes cytosolic degradation of Nrf2 [8]. PDTC treat-
ment decreased Keap1 levels, likely reducing Nrf2 deg-
radation and promoting Nrf2 accumulation. In addition,
Nrf2 degradation may be reduced by GSK3β inhibition.
GSK3β is a kinase that modulates activity of Nrf2-ARE
signaling by promoting Keap1-independent Nrf2 degrad-
ation [66, 67]. Direct inhibition of GSK3β results in nu-
clear accumulation of Nrf2, indicating that GSK3β is a
fundamental element of Nrf2-ARE regulation after oxi-
dative injury [68, 69]. It is known that PDTC exerts its
protective effects via reduction of activated GSK3β sig-
naling in AD [41] and in neonatal hypoxia-ischemia
[34]. In agreement with previous studies, we found that
PDTC also dampens GSK3β activity in primary astro-
cytes. Direct inhibition of GSK3β also induced Nrf2 in
the current study, although to a lesser extent than
PDTC. Inhibition of kinases upstream of GSK3β includ-
ing MAPK and PI3K/Akt failed to influence Nrf2 induc-
tion by PDTC, although this is likely due to redundancy
within the kinase pathways. Taken together, it seems that
GSK3β is implicated in PDTC-mediated Nrf2 induction.
As the activity of GSK3β is known to be influenced by
metals [70, 71] and PDTC is reported to bind metals
and transport them inside cells, the observed effects
could also be related to the metal-chelating property of
PDTC [72, 73].
Copper is a trace element that is essential for cellular
function. Disturbances in copper homeostasis are detri-
mental and lead to disease [74, 75]. We show here that a
2-week treatment of mice with PDTC results in an
increased copper concentration in the brain. As copper
is known to induce the ERK [76] and Akt pathways [77],
we hypothesize that the PDTC-mediated increase in
intracellular copper could trigger the phosphorylation of
ERK and Akt, leading to reduced GSK3β activity (in-
creased inhibitory phosphorylation) [78]. In support of
our hypothesis, it has been shown that copper exposure
induces nuclear accumulation of Nrf2 and induces pro-
tective Nrf2 signaling [79], which is blocked in Nrf2-
deficient cells [80]. It is of interest to note that Keap1,
the stress sensor and negative regulator of Nrf2, quanti-
fies cellular stress by monitoring intracellular levels of
metals such as zinc [81]. Therefore, it seems plausible
that PDTC-mediated metal transport is responsible for
the observed induction of the Nrf2 signaling in this study.
Further studies are clearly required to thoroughly assess
the interplay between metal homeostasis and Nrf2.
Our findings on the inhibition of GSK3β by PDTC are
particularly interesting in the context of AD, where
GSK3β not only phosphorylates tau protein [82] but also
affects the expression of Aβ degrading enzymes [83].
The interplay between Aβ and Nrf2 is highlighted by
our finding that treatment of cells with Aβ resulted in
increased expression of the Nrf2 target gene HO-1 in as-
trocytes, in line with previous studies [84] and reported
increases in HO-1 expression in the AD brain [85]. Fur-
thermore, the increase in HO-1 expression, and that of
Nrf2 target gene GCLM, was significantly augmented in
astrocytes co-treated with PDTC and Aβ. It should be
noted that although HO-1 expression can be regulated
by other transcription factors besides Nrf2 [86, 87] and
therefore making it possible that HO-1 induction may
additionally involve other transcription factors, the in-
duction of GCLM indicates that Nrf2 signaling is in-
duced. These results indicate that while Aβ itself has the
potential to slightly induce Nrf2 target gene expression,
enhanced up-regulation of the protective pathway by
PDTC is achieved in an elevated Aβ environment. These
data suggest that an AD-related environment is espe-
cially favorable for effective induction of protective Nrf2
signaling by PDTC.
We observed a reduction of hippocampal lipid peroxi-
dation with PDTC treatment in tissue homogenates in
vivo, suggesting that a more antioxidative environment
has been induced. That we detect elevated hydroperox-
ides in Nrf2-deficient mice supports the notion that
Nrf2 is involved in the decreased lipid peroxidation in-
duced by PDTC. The fact that we did not observe a sig-
nificant induction of other Nrf2-ARE pathway markers
in tissue homogenates in vivo is not completely unex-
pected given the in vitro data shown in this study: robust
PDTC-mediated activation of Nrf2 signaling was only
observed in astrocytes. While astrocytes have tradition-
ally been viewed as the most abundant cell type in the
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brain, recent reports demonstrate that in the mouse
brain, approximately 35 % of the cells are non-neuronal
[88, 89]. This 35 % includes astrocytes, microglia, oligo-
dendrocytes, and various precursor cells. The homoge-
nized tissue samples used in this study for mRNA and
protein expression analyses exclude the possibility of dis-
cerning the responses of specific cell types; hence, any
astrocyte-specific effects will be masked by the presence
of other cell types in the tissue homogenates. Indeed,
our immunohistochemical analyses of brain showed
HO-1 induction in only certain cell types in vivo, indi-
cating that PDTC exerts cell-specific effects also in the
brain. It should be noted that the current study did not
assess the potential of PDTC to induce Nrf2-ARE signal-
ing in microglial cells. It is therefore possible that the
beneficial effects of PDTC on Nrf2 induction also occur
in these cells.
Finally, strong in vitro activation of Nrf2 signaling was
observed in the presence of Aβ. As the current study
utilized only WT mice for assessing the effects of PDTC
on Nrf2-ARE induction, it can be speculated that PDTC
may also more strongly induce Nrf2-ARE signaling in
vivo if Aβ is present. Given that the Nrf2 pathway is im-
paired in AD mice and in the brains of AD patients [12,
15], further studies are needed to assess the contribution
of Aβ to PDTC-induced Nrf2 activation in vivo.
Conclusions
In this study, we have identified a novel function of the
metal chelator PDTC: the activation of Nrf2 signaling in
astrocytes. Furthermore, activation of Nrf2 was aug-
mented in the presence of Aβ, and PDTC decreased brain
lipid peroxidation. These effects may contribute to the
neuroprotection we and others have observed for PDTC
in models of AD [41, 42]. The identification of safe, well-
tolerated molecules that cross the blood-brain barrier to
activate the Nrf2-ARE pathway is important, as these may
have a valuable role in protecting the brain from oxidative
stress associated with neurodegenerative diseases.
Additional files
Additional file 1: Figure S1. Effect of PDTC treatment on viability of
astrocytes and hippocampal neurons. (A) Primary cultures of neonatal
astrocytes were treated with increasing concentrations of PDTC for 24 h,
after which cell viability was measured by LDH release and (B) MTT
reduction assays. (C) Hippocampal neuron survival following 24-h PDTC
treatment was measured by manual counting of viable cells/all cells
following Hoechst staining. Data are expressed as mean % of viable
cells ± SD and normalized to control cells in (B) and (C). **p < 0.001
relative to corresponding control.
Additional file 2: Figure S2. Absence of Nrf2 immunostaining in
Nrf2−/− astrocytes. Representative Nrf2 immunostaining images of
primary Nrf2−/− astrocytes treated with 100 μM PDTC for 4 h. DAPI
staining was carried out to visualize nuclei. Scale bar = 40 μm.
Additional file 3: Figure S3. Inhibition of kinases does not alter Nrf2
induction by PDTC. (A,E) Representative immunoblots with antibodies
against Nrf2, HO-1, and GAPDH in primary neonatal astrocytes co-treated
for 4 h with PDTC and (A) SL327 or PD198306 (MEK inhibitors), or (E)
LY294002 (PI3K inhibitor) or FPA124 (Akt inhibitor). (B,F) Quantification
of Nrf2 and (C,G) HO-1 protein expression after 4 h co-treatment of
astrocytes with PDTC and indicated inhibitors. Data are expressed as fold
change over control cells in absence of inhibitors, normalized to GAPDH±
SD. (D,H) Exported glutathione after 4 h PDTC co-treatment of neonatal
astrocytes in presence of (D) SL327 or PD98059 (MEK inhibitors), or (H)
LY294002 or PI828 (PI3K inhibitors), FPA124 or 10-DEBC (Akt inhibitors). Data
expressed as nanomole glutathione released into the medium per well.
Additional file 4: Figure S4. Effect of kinase inhibitors on viability of
astrocytes. (A) Cell viability was measured by LDH release and (B) MTT
reduction in primary neonatal astrocytes co-treated with PDTC and
10 μM indicated inhibitors for 4 h. LDH release expressed as mean
percentage of initial total cellular LDH activity ± SD. MTT reduction
expressed as mean percentage of viable cells ± SD normalized to control
cells. *p < 0.05 relative to corresponding control cells; ap < 0.05 relative to
corresponding treatment without PDTC.
Additional file 5: Figure S5. Expression of Nrf2-pathway related genes
and proteins in mouse hippocampi following PDTC treatment. WT mice
were treated with PDTC in the drinking water at a dose of 75 mg/kg/day
for 2 weeks, or for 9 months at a dose of 20 mg/kg/day. (A) HO-1, (B)
NQO1, and (C) Nrf2 mRNA expression levels were
measured by quantitative RT-PCR in hippocampal samples and are
presented as mean relative expression normalized to β-actin ± SD. (D)
Representative immunoblots with antibodies against Nrf2, NQO1, and
β-actin with hippocampal samples from mice treated 2 weeks with PDTC
at a dose of 75 mg/kg/day. (E) Quantification of hippocampal Nrf2
protein levels after PDTC treatment of mice. Data are expressed as fold
change over control cells normalized to β-actin ± SD. (F) Quantification of
hippocampal NQO1 protein levels after PDTC treatment of mice. Data are
expressed as fold change over control cells normalized to β-actin ± SD.
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